SensPD

Company Overview

Snapshot

Founded in January 2015 by Raffi Rembrand and Mor Stavsky, SensPD operates with 1–10 employees. The company has raised $280,000 across three funding rounds. In June 2018, SensPD secured a grant from the European Commission.

Business overview

SensPD is a Health Tech & Life Sciences company focused on developing an objective method for the early detection of autism. The company's core technology utilizes Oto-Acoustic-Emission (OAE) devices, commonly used for hearing screenings, with proprietary modifications to assess sensory perception system performance. This non-invasive, cost-effective solution aims to provide early autism detection in newborns, serving global markets and operating within the Digital Health and Medical Technologies sectors.

Strategic signal

In September 2019, SensPD was featured on Worldwide Business with kathy ireland®, highlighting its revolutionary method for detecting autism at birth. This media exposure signals growing recognition and validation of SensPD's innovative diagnostic approach within the medical community and broader public, potentially accelerating adoption and strategic partnerships.

Company Intelligence Q&A

What is SensPD's primary mission?

SensPD's mission is to ensure that all newborns are properly tested for autism, aiming to eliminate the fear and worry associated with late autism detection for families.

What was a key media appearance for SensPD?

In September 2019, SensPD introduced its method to detect autism at birth on Worldwide Business with kathy ireland®.

What was the focus of SensPD's news in November 2017?

In November 2017, news highlighted how SensPD's technology could enable newborns to be screened for autism.

When did SensPD enter its first round of funding?

In January 2018, SensPD entered its first round of funding to launch its software technology for early autism detection in newborns.